Testing New CMV Inhibitors with a Special Virus
Author Information
Author(s): He Ran, Sandford Gordon, Hayward Gary S, Burns William H, Posner Gary H, Forman Michael, Arav-Boger Ravit
Primary Institution: Johns Hopkins University School of Medicine
Hypothesis
Can recombinant luciferase-expressing human cytomegalovirus (CMV) be used to evaluate CMV inhibitors effectively?
Conclusion
The pp28-luciferase reporter system is a rapid and sensitive method for screening anti-CMV compounds.
Supporting Evidence
- The pp28-luciferase virus showed a wider dynamic range of luciferase expression.
- Luciferase expression correlated highly with plaque reduction and real-time PCR results.
- The assay can be performed rapidly, making it suitable for high-throughput screening.
Takeaway
Researchers created a special virus that glows to help find new medicines to fight a common virus that can make people very sick.
Methodology
The study involved constructing recombinant CMV viruses expressing luciferase and testing their ability to indicate the effectiveness of antiviral compounds.
Limitations
The study may not account for all variables affecting CMV replication and drug efficacy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website